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Abstract: The objective of this study was to
assess the effect of sublingual valsartan in a
group of patients with hypertensive urgency.
Forty-one patients with hypertensive urgency
and systolic blood pressure >200 mmHg,
diastolic blood pressure >100 mmHg were
studied in an emergency room. Supine blood
pressure readings were taken and the patients
were given 80 mg of valsartan sublingually.
Blood pressure and heart rate were recorded
at 15 min intervals over a 90 min period.
Systolic blood pressure decreased from
211.22±14.65 mmHg to 158.17±15.48
mmHg, diastolic blood pressure dropped from
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Introduction
Hypertensive crisis is defined as a severe elevation in
blood pressure (BP) and is classified as either urgency or
emergency. The presence of acute or ongoing end-organ
damage, such as myocardial infarction, left ventricular
insufficiency, acute renal insufficiency and hypertensive
encephalopathy, constitutes a hypertensive emergency,
where the absence of such complications is known as a
hypertensive urgency (1-3). The goal of treatment in a
hypertensive urgency is a gradual reduction of blood
pressure. The appropriate medication for the treatment
of hypertensive urgencies should have the following
properties: availability for nonparenteral the ability to
administration and decrease BP to a plateau (4,5).
Several oral or intravenous drugs are available for the
treatment of hypertensive crisis, such as captopril,
enalapril, sodium nitroprusside and nitroglycerin (6,7).
Recently, a review of multiple clinical trials has revealed
that short-acting nifedipine may cause an increase in
mortality. It is recommended that patients with acute
coronary syndrome should not receive short-acting
nifedipine (8). Several angiotensin II receptor blockers,
including irbesartan, losartan, telmisartan, condesartan,
cilexetil and valsartan, are used for the treatment of
patients with hypertension. Valsartan blocks
vasoconstriction caused by angiotensin II and is orally
active. The onset of the hypotensive effect of angiotensin
II receptor blockers appear to be more gradual than that

120.12±13.44 mmHg to 93.05±6.01
mmHg. The differences were statistically
significant. The heart rate decreased from
87.90±13.47 beats per minute to
82.59±10.84 beats per minute. The results
of our study indicate that sublingual valsartan
is an effective drug in patients with
hypertensive urgency and it is easy to use
sublingually because it is in a capsule form and
it is side-effect free. Further work is required
to assess the effect of sublingual valsartan in
patients with hypertensive urgency.
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associated with angiotensin converting enyzme inhibitors,
perhaps related to the lack of the bradykinin-potentiating
capability of those agents (9,10).
The purpose of this study was to assess the effect of
sublingual valsartan in patients with hypertensive
urgency.

Mater›als and Methods
Fourty-one patients with hypertensive urgency who
had discontinued antihypertensive drug or drugs by
themselves 48 h prior were chosen for this study. On
admission, all patients had documented hypertension
and had been treated previously with various
antihypertensive agents irregularly. Patients with
systolic blood pressure (SBP) over 200 mmHg and
diastolic blood pressure (DBP) over 100 mmHg were
chosen for the study. Seventeen of these patients were
men and the others were women. Their ages ranged
from 29 to 68 years (mean 52.9±10.0 years). Twenty
patients had associated ischemic heart disease with
stable angina pectoris. Their resting electrocardiograms
were normal. Ten patients had headache without
neurologic signs and 11 patients had dizziness without
neurologic signs. Fifteen patients had diabetes mellitus.
Renal function was normal in all patients. Secondary
forms of hypertension were ruled out after careful
clinical and laboratory evaluations.
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Three supine blood pressure readings using a
standard sphygmomanometer were taken at 5 min
intervals prior to the study. The DBP was recorded at the
disappearence of Korofkoft sounds (phase V). The heart
rate was also recorded. A valsartan capsule containing a
dose of 80 mg was opened and given sublingually. The
patients were asked to keep the drug in his/her mouth
without swallowing. The valsartan capsules used were the
standard peroral Diovan capsules manufactured by
Novartis Pharma AG, Switzerland. Blood pressure was
measured at 15, 30, 60, 90 min following valsartan
administration. Statistical analysis, which consisted of
comparing the onset blood pressure values with
pressures at 15, 30, 60, 90 min was performed by the
paired-t-test using SPSS for Windows Rel. 0.0.

reduction of 33.5%, and the DBP of 29.0% by 90 min.
The heart rate decreased from 87.90±13.47 beats/min
to 82.59±10.84 beats/min. Hypotension did not develop
in any patient.
In addition to the significant overall decreases in SBP
and DBP readings during the 90 min period, the
measured values for both these pressures declined
significantly from the onset to each of the 15, 30, 60, 90
min measurements. The declines in SBP and DBP at these
points of measurement is given in the Table. The Figure
gives the graphical representation the mean values of SBP
and DBP at each reading.
None of the patients showed any adverse reactions to
valsartan during the study.

Informed consent was obtained from the participants.
Discussion
Results
Forty-one patients (17 men and 24 women, mean age
52.90 ±9.09 years) were included in the study. The SBP
decreased from 211.22±14.65 mmHg to 158.17±15.48
mmHg at 90th min (p<0.01). In the same time interval,
the DBP decreased from 120.12±13.44 mmHg to
93.05±6.01 mmHg (p<0.01). Hence, the SBP showed a

The level to which blood pressure should be reduced
in patients with hypertensive emergencies and urgencies
is still unclear and controversial. The initial aims of
therapy should be the reduction of blood pressure by onethird or 20 to 30 percent (11-13). Hypertensive urgency
is between mild-moderate hypertension and hypertensive
emergency from the point of view of severity. In
hypertensive emergencies, blood pressure should be
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Table.

15 min

30 min

60 min

90 min

The mean pre-and postdose SBP and DBP (mmHg) and % reduction.
Onset

15 min

reduction
%

30 min

reduction
%

60 min

reduction
%

90 min

reduction
%

SBP

211.22±14.65

187.80±16.92

12.2

173.41±16.37

22

166.71±15.91

26.3

158.17±15.48

33.5

DBP

120.12±13.44

111.95±10.77

7.1

104.88±9.05

14.3

99.63±7.53

20.0

93.05±6.01

29
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lowered within minutes with parenteral agents to prevent
critical end-organ damage. But in hypertensive urgencies,
blood pressure can be lowered more slowly over several
hours, often with oral agents, to avoid a detrimental fall
in blood pressure (5,13). No specific drug has been
shown to be particularly efficacious in the treatment of
hypertensive urgencies.
Angiotensin II receptor antagonists block a number of
angiotensin II effects that are relevant to the
pathophysiology of cardiovascular disease, including
vasocostriction, renal sodium reabsorbtion, aldosteron,
vasopressin secretion and sympathetic activation. We did
not find any reports in the literature about the effect of
valsartan used sublingually for the treatment of
hypertensive urgencies. Recently we reported on the
comparison of the hypotensive effect of sublingual
losartan with that of sublingual captopril and nifedipine
in 1999. In this study, losartan , an Angiotensin II
receptor antagonist, decreased the mean SBP from
190.50 mmHg to 146.25 mmHg, and mean DBP from
109.25 mmHg to 88.50 mmHg at 90 min (15).

In this study, forty-one patients were in hypertensive
urgency and we used valsartan, a new angiotensin II
receptor antagonist, in a dose of 80 mg sublingually. At
90 min a 33.5% reduction of SBP and a 29.0% reduction
of DBP was achieved by sublingual valsartan.
We concluded that valsartan sublingually administered
is an effective and safe alternative drug for managing
hypertensive urgencies. Valsartan can be used as a firstline drug in emergency urgencies, since it is produced in
capsule form and is easy to administer. Further studies
are obviously necessary to compare valsartan to other
antihypertensive regimens used for the treatment of
hypertensive urgencies.
Correspondence author:
Yüksel GÖKEL
Department Emergency, Faculty of Medicine,
Çukurova University
01330, Adana - TURKEY

References
1.

Bales A. Hypertensive crisis: How to tell
if it's an emergency or an urgency.
Postgraduate Medicine 105: 119-130,
1999.

6.

Grossman E, Ironi AN, Messerli FH.
Comparative tolerability profile of
hypertensive crisis treatments. Drug Saf
19 (2): 99-122, 1998.

2.

Gifford RW Jr. The fifth report of the
Joint National Committee on Detection,
Evaluation, and Treatment of High
Blood Pressure (JNCV). Arch Intern Med
153: 154-183, 1993.

7.

Ceyhan B, Karaaslan Y, Caymaz O, Oto
A, Oram E, Oram A, Ugurllu S.
Comparison of sublingual captopril and
sublingual nifedipine in hypertensive
emergencies. Japan J Pharmacol 52:
189-193, 1990.

3.

4.

5.

Marigliano V, Santilli D, Fiorani M,
Ariani A, Cacciafesta M, Ferry C,
Piccirillo G. Hypertensive emergencies
in old age: effects of angiotensin
converting enzyme inhibition. J
Hypertens 6 (1): 91-93, 1998.
Angeli P, Chiesa M, Caregaro L, Merkel
C, Sacerdoti D, Rondana M, Gatta A.
Comparison of sublingual captopril and
nifedipine in immediate treatment of
hypertensive emergencies. Arch Intern
Med 151: 678-682, 1991.
Kitiyakara C, Guzman NJ. Malignant
hypertension
and
hypertensive
emergencies. J Am Soc Nephrol 9(1):
133-142, 1998.

8.

Furberg CD, Psaty BM, Meyer JV.
Nifedipine: dose related increase in
mortality in patients with coronary heart
disease. Circulation 92 (5): 19261931, 1995.

9.

Siragy H. Angiotensin II receptor
blockers: review of the binding
characteristics. Am J Cardiol 84 (10): 38, 1999.

10.

Singh NK, Goyal RK. New classes of
antihypertensive drugs: therapeutic
potentials. Clin Exp Hypertens 21 (1-2):
137-143, 1999.

11.

Williams GH. Hypertensive vascular
disease. Harrison's principles of Internal
Medicine (Eds. AS Fauci and E
Braunwald) McGraw-Hill. New York
1998, pp: 1380-1394.

12. Mann SJ, Atlas SA: Hypertensive
Emergencies.
Hypertension,
Pathophysiology,
Diagnosis
and
Management (Eds. JH Laragh and BM
Brenner) Raven Press. New York 1995,
pp: 3009-3022.
13. Kaplan NM: Clinical Hypertension,
Williams and Wilkins. Baltimore 1998,
pp: 265-280.
14.

Hirschl MM, Herkner H, Bur A,
Woisetschlager C, Gamper G, Frossard
M, Laggner AN. Course of blood
pressure within the first 12 h of
hypertensive urgencies. J Hypertens 16
(2): 251-255, 1998.

15.

Gökel Y, Satar S, Paydafl S. A
comparison of the effectiveness of
sublingual losartan, sublingual captopril
and
sublingual
nifedipine
in
hypertensive urgency. Tr J Med Sci 29:
655-660, 1999.

567

